Paysign Q2 revenue up 33%, beats analyst estimates
Overview
Paysign Q2 2025 revenue grows 33.1%, beating analyst expectations
Adjusted EBITDA for Q2 2025 beats consensus, rising 101.8% yr/yr
Company added 123 net plasma centers, exiting quarter with 607 centers
Outlook
Paysign revises full-year 2025 revenue to $76.5 mln-$78.5 mln
Company expects Q3 2025 revenue between $19.5 mln and $20.5 mln
Paysign sees plasma revenue flat, pharma revenue up 145% in 2025
Company expects Q3 2025 gross profit margin around 59%
Result Drivers
PHARMA GROWTH - Pharma patient affordability revenue surged 189.9% due to new programs and increased claims processing
PLASMA CHALLENGES - Plasma revenue declined 4.7% amid industry oversupply, despite adding 123 net plasma centers
COST INCREASES - Costs rose due to growth in pharma programs, wage inflation, and onboarding of new plasma centers
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $19.08 mln | $18.70 mln (5 Analysts) |
Q2 EPS | $0.02 | ||
Q2 Net Income | $1.39 mln | ||
Q2 Adjusted EBITDA | Beat | $4.51 mln | $4.39 mln (5 Analysts) |
Q2 Gross Margin | 61.6% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Paysign Inc is $8.00, about 10.5% above its August 4 closing price of $7.16
Press Release:
